Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Stopped Closed early due to lack of funding
Conditions
- Burkitt Lymphoma
- CD20-Positive Neoplastic Cells Present
- Diffuse Large B-Cell Lymphoma
- Indolent Non-Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions
- BIOLOGICAL: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
- PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
- DRUG: Carmustine
- DRUG: Clearing Agent
- DRUG: Cytarabine
- DRUG: Etoposide
- RADIATION: Indium In 111-DOTA-Biotin
- OTHER: Laboratory Biomarker Analysis
- DRUG: Melphalan
- PROCEDURE: Peripheral Blood Stem Cell Transplantation
- OTHER: Pharmacological Study
- RADIATION: Yttrium Y 90-DOTA-Biotin
Sponsor
Fred Hutchinson Cancer Center
Collaborators